LBF20407HO04: Difference between revisions

No edit summary
No edit summary
 
(13 intermediate revisions by 2 users not shown)
Line 5: Line 5:
{{Metabolite
{{Metabolite
|LipidBank=DFA8105
|LipidBank=DFA8105
|LipidMaps=-
|LipidMaps=LMFA03060050
|SysName=8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid
|SysName=(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid
|Common Name=&&8S,15S-dihydroxy-5Z,9E,11Z,13E-eicosatetraenoic acid&&
|Common Name=&&(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid&&8,15-DiHETE&&
|UV Spectra=<FONT FACE="Symbol">l</FONT>max: 269 nm <FONT FACE="Symbol">e</FONT>: 40,000
|UV Spectra= lambda max: 269 nm epsilon : 40,000
|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]];>.
|Source=8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]].
|Chemical Synthesis=
|Chemical Synthesis=
|Metabolism=
|Metabolism=
|Symbol=8(S),15(S)-DiHETE
|Biological Activity=8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5  &mu; M but is not chemotactic for neutrophils [[Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893|{{RelationTable/GetFirstAuthor|Reference:Morita_E:Schroder_JM:Christophers_E:,J. Immunol.,1990,144,1893}}]]. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain [[Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384|{{RelationTable/GetFirstAuthor|Reference:Oliw_EH:,Biochim. Biophys. Acta,1984,795,384}}]].
}}
{{MassbankSpectra|
UT000199
UT000200
UT000201
UT000202
UT000203
UT000204
UT000205
UT000206
UT000207
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Latest revision as of 00:00, 17 January 2014

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



(8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid
LBF20407HO04.png
Structural Information
(8S,15S) -Dihydroxy- (cis-5,trans-9,cis-11,trans-13) -eicosatetraenoic acid
  • (8S,15S) -Dihydroxy- (5Z,9E,11Z,13E) -eicosatetraenoic acid
  • 8,15-DiHETE
8(S),15(S)-DiHETE
Formula C20H32O4
Exact Mass 336.23005951199997
Average Mass 336.46567999999996
SMILES C(CCC(C=CC=CC=CC(CC=CCCCC(O)=O)O)O)CC
Physicochemical Information
8(S),15(S)-DiHETE is formed when15(S)-HETE is subjected to further oxidation by 15-lipoxygenase Morita_E et al..
8(S),15(S)-diHETE causes chemotaxis of human eosinophils with an ED _{50} of 1.5 μ M but is not chemotactic for neutrophils Morita_E et al.. 8(S),15(S)-diHETE exhibits hypoalgesic activity by antagonizing the hyperalgesic activity of 8(R),15(S)-diHETE and LTB 4 when measuring nociceptive activity in the rat hindpaw model of pain Oliw_EH .
Spectral Information
Mass Spectra
UV Spectra λ max: 269 nm ε : 40,000
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20407HO04 See above. Morita_E et al. 1990